# Atopic Dermatitis

A severity- and site-directed approach to atopic dermatitis prioritizes topical anti-inflammatory treatment, proactive relapse prevention, and timely systemic escalation when disease remains uncontrolled, sleep-disrupting, or extensive despite optimized topical care.

**Clinical question:** How should clinicians assess atopic dermatitis severity and escalate topical or systemic treatment for persistent disease?

Updated: 2026-09-15T23:14:49.021590+00:00

## What matters in practice
- Use a reproducible clinician measure such as EASI plus a patient-reported measure such as POEM when symptom burden and visible inflammation diverge; EASI and POEM correlate only moderately. [18][19]
- Topical corticosteroids remain first-line anti-inflammatory treatment; an acute flare regimen of mid- to high-potency treatment once daily for 2 to 4 weeks and proactive low- to medium-potency weekend treatment are described approaches. [22]
- Select nonsteroidal topical agents when corticosteroid toxicity is a concern, for sensitive sites, or when repeated treatment is needed; calcineurin inhibitors, PDE-4 inhibitors, and topical JAK inhibitors are alternatives. [16]
- For moderate-to-severe disease uncontrolled with optimized topical therapy, systemic choices include dupilumab and oral JAK inhibitors; high-dose upadacitinib has among the greatest short-term efficacy across multiple patient-important outcomes, whereas dupilumab and IL-13 biologics have intermediate effectiveness and favorable safety profiles. [23]
- Avoid routine systemic corticosteroids for chronic management; contemporary reviews describe systemic corticosteroids as generally discouraged because of safety concerns. [8]

## Document inflammatory severity and patient burden before escalating therapy

Treatment escalation should follow confirmation of persistent active dermatitis, not itch alone.

At baseline and at treatment-change visits, document extent and signs with EASI when a clinician-assessed longitudinal metric is needed. EASI scores range from 0 to 72; values of 7 or less, 8 to 21, 22 to 50, and 51 to 72 correspond to mild, moderate, severe, and very severe disease, respectively. [20] Record a patient-reported outcome such as POEM when itch, sleep loss, or day-to-day burden is driving escalation, because EASI and POEM show only moderate correlation. [18][19]

Interpret change relative to baseline rather than relying only on an absolute EASI change. In an observational study, one-grade improvement in physician global assessment was associated with approximately 50% EASI reduction, while percent EASI responses had similar interpretation across mild, moderate, and severe baseline disease. [17] A patient with limited visible eczema but high POEM may require reassessment for xerosis, sleep disruption, treatment tolerability, or an alternate contributor to symptoms rather than automatic systemic escalation. [18][19]

Before declaring topical treatment failure, verify the diagnosis and distribution. The United Kingdom diagnostic criteria can support probable atopic dermatitis; discordant anatomy or timing should prompt consideration of contact dermatitis, acute viral exanthem, or immune deficiency-associated dermatoses. [19] Chronic dermatitis present from birth is not the expected pattern for immune deficiency-associated skin disease in the cited diagnostic framework. [19]
- Use EASI when objective severity or systemic-treatment response must be tracked over time. [20]
- Use POEM or PO-SCORAD to quantify patient-experienced burden in routine practice; these measures are less time-consuming than EASI or SCORAD. [19]
- Reassess diagnostic alternatives when morphology, distribution, or chronology is atypical for atopic dermatitis. [19]

*Severity measures support different treatment decisions. [17][18][19][20]*

| Measure | What it captures | Decision use | Actionable interpretation |
| --- | --- | --- | --- |
| EASI | Erythema, edema/papulation, excoriation, lichenification, and affected area; total score 0-72. [20] | Objective baseline and response tracking. | Scores 8-21 indicate moderate, 22-50 severe, and 51-72 very severe disease. [20] |
| POEM | Patient-reported eczema burden. [19] | Quantify itch- and sleep-related impact that may not parallel skin findings. | Do not substitute low EASI for low burden; EASI and POEM correlate only moderately. [18] |
| SCORAD | Clinical signs and extent plus subjective pruritus and sleep assessment. [19] | Alternative comprehensive severity assessment. | Less practical than patient-reported tools or EASI for many routine visits. [19] |

## Treat active lesions, then prevent relapse at recurrent sites

Persistent disease often reflects inadequate anti-inflammatory intensity, duration, or maintenance rather than treatment resistance.

Use topical corticosteroids as first-line anti-inflammatory therapy for flares and maintenance of mild-to-moderate atopic dermatitis. [22] One described flare strategy is a mid- to high-potency topical corticosteroid once daily for 2 to 4 weeks; treatment quantity can be estimated with fingertip units, where 1 fingertip unit is approximately 0.5 g and covers about two adult hand areas, or 2% body surface area. [22] Select potency according to lesion thickness, anatomic site, age, and anticipated duration, recognizing that guideline potency recommendations vary. [24]

After control of recurrent disease, use proactive therapy rather than waiting for full relapse. A cited regimen uses low- to medium-potency topical corticosteroid once daily on weekends. [22] Guidelines reviewed in a Cochrane analysis generally recommended weekend proactive topical corticosteroid use, although the evidentiary support varied by region and guideline. [24]

Monitor patients requiring prolonged or extensive high-potency topical corticosteroids for local toxicity, including atrophy, striae, rosacea, perioral dermatitis, acne, and purpura. [22] Systemic adverse effects are uncommon, but prolonged high-potency exposure can suppress the hypothalamic-pituitary-adrenal axis and produce Cushing syndrome manifestations. [22] Recurrent adverse effects or need for continuous high-potency therapy should trigger transition to a steroid-sparing topical agent and consideration of systemic disease control.
- Acute flare: mid- to high-potency topical corticosteroid once daily for 2 to 4 weeks. [22]
- Maintenance of recurrent sites: low- to medium-potency topical corticosteroid once daily on weekends. [22]
- Escalate beyond a topical-only strategy when extensive disease, repeated flares, or major itch and sleep burden persist despite an adequate topical course. [19][23]

### When to use nonsteroidal topical therapy

Use a topical calcineurin inhibitor, PDE-4 inhibitor, or topical JAK inhibitor when repeated treatment of sensitive skin, corticosteroid adverse effects, or a need to reduce corticosteroid exposure makes a nonsteroidal agent preferable. [16] These therapies are alternatives rather than replacements for a severity-based anti-inflammatory plan; continued objective and patient-reported outcome assessment determines whether topical therapy is sufficient. [19]

*Topical treatment choices and escalation triggers. [16][22][24]*

| Clinical situation | Preferred topical strategy | Important tradeoff or next step |
| --- | --- | --- |
| Active flare requiring anti-inflammatory control | Mid- to high-potency topical corticosteroid once daily for 2-4 weeks. [22] | Monitor local toxicity with recurrent or prolonged use. [22] |
| Previously involved sites with frequent recurrence | Low- to medium-potency topical corticosteroid once daily on weekends. [22] | Proactive treatment is intended to delay relapse. [22][24] |
| Need to limit corticosteroid exposure | Topical calcineurin inhibitor, PDE-4 inhibitor, or topical JAK inhibitor. [16] | Reassess disease control; persistent burden warrants systemic-treatment consideration. [19][23] |
| Continuous high-potency steroid need or poor control after an adequate regimen | Reevaluate diagnosis, adherence, distribution, and severity measures. [19][22] | Consider phototherapy or systemic treatment for moderate-to-severe disease. [21][23] |

## Choose systemic therapy by efficacy priority, safety profile, and treatment constraints

Systemic treatment is appropriate for moderate-to-severe disease inadequately controlled with topical therapy.

For refractory moderate-to-severe atopic dermatitis, systemic options include biologics, oral JAK inhibitors, phototherapy, and conventional immunosuppressive agents. [1][21][23] In a network meta-analysis of 149 randomized trials involving 28,686 patients with moderate-to-severe disease, high-dose upadacitinib was among the most effective therapies for five of six patient-important outcomes; high-dose abrocitinib and low-dose upadacitinib were among the most effective for two outcomes. [23] Oral JAK inhibitors are characterized as highly effective, rapid-onset treatments for moderate-to-severe atopic dermatitis. [10]

Choose a biologic when a favorable comparative safety profile is prioritized over maximal short-term efficacy. Dupilumab, lebrikizumab, and tralokinumab were of intermediate effectiveness and among the safest systemic options in the network meta-analysis. [23] Dupilumab is FDA approved down to age 6 months; upadacitinib and abrocitinib are approved for patients 12 years and older, while tralokinumab is identified as an IL-13 antagonist option. [1][6]

Abrocitinib is FDA indicated for adults and patients 12 years and older with refractory moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic drug products, including biologics, or when those therapies are inadvisable. [1] When considering an oral JAK inhibitor, explicitly weigh the anticipated benefit of rapid, high-level disease control against class safety considerations and the need for medication-specific prescribing review; do not use systemic corticosteroids as routine long-term management, because they are generally discouraged for safety reasons. [8][10]
- Prioritize rapid, high-efficacy control: an oral JAK inhibitor may be appropriate after individualized risk assessment. [10][23]
- Prioritize comparative safety and established biologic use: consider dupilumab or an IL-13-targeted biologic. [6][23]
- Consider phototherapy or conventional systemic immunosuppression when targeted agents are unsuitable, unavailable, or contraindicated. [21]
- Avoid making chronic oral corticosteroids the maintenance plan. [8]

### Where phototherapy and conventional immunosuppression fit

Phototherapy and photochemotherapy, including psoralen-ultraviolet A, are treatment options for chronic severe atopic dermatitis. [21] Conventional systemic options listed for more severe dermatitis not responding to topical therapy include cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil. [21] Their role is most practical when targeted systemic treatment is unsuitable or inaccessible and when the monitoring burden is acceptable for the individual patient.

*Systemic-treatment selection for uncontrolled moderate-to-severe atopic dermatitis. [1][6][10][21][23]*

| Clinical priority | Reasonable treatment direction | Evidence-based discriminator |
| --- | --- | --- |
| Fast, high-level short-term disease control | Oral JAK inhibitor. | High-dose upadacitinib was among the most effective interventions for five of six patient-important outcomes; oral JAK inhibitors are rapid-onset therapies. [10][23] |
| Comparative safety emphasis | Dupilumab, lebrikizumab, or tralokinumab. | These biologics had intermediate effectiveness and were among the safest options in the network meta-analysis. [23] |
| Refractory disease in a patient aged 12 years or older after other systemic therapy is ineffective or inadvisable | Abrocitinib, within its FDA-indicated population. | FDA indication includes refractory moderate-to-severe disease not adequately controlled with other systemic drugs, including biologics, or when those therapies are inadvisable. [1] |
| Targeted therapy unsuitable or unavailable | Phototherapy or conventional systemic immunosuppression. | Phototherapy, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil are recognized options for more severe disease. [21] |

## Use parallel objective and patient-reported response targets to change course

Visible clearance and patient experience should both determine whether therapy is continued or changed.

At each reassessment, compare EASI and a patient-reported burden measure with baseline. An EASI reduction of approximately 50% corresponded to one-grade improvement in physician global assessment in a prospective observational study. [17] If EASI improves while itch, sleep disturbance, or POEM remains high, investigate ongoing xerosis, excoriation, treatment adverse effects, and diagnostic overlap before labeling the systemic agent ineffective. [18][19]

If objective inflammation and patient burden both remain substantial after an adequate topical regimen, move beyond repeated rescue topical corticosteroid cycles. For moderate-to-severe disease, compare systemic options using the patient’s required speed of relief, age eligibility, comparative safety priorities, and feasibility of phototherapy or conventional systemic treatment. [1][6][10][21][23] If control is achieved, continue relapse prevention at historically active sites rather than discontinuing all anti-inflammatory topical treatment solely because visible lesions have cleared. [22][24]
- Track EASI response from baseline; percent improvement is more comparable across baseline severity strata than absolute point change. [17]
- Track itch and sleep burden separately because clinical extent and patient-reported burden may diverge. [18][19]
- Change strategy when both inflammatory signs and patient burden persist despite an adequate treatment trial. [19][23]

*Response patterns that should alter the next clinical step. [17][18][19][22][23][24]*

| Observed response | Interpretation | Next action |
| --- | --- | --- |
| EASI falls by about 50% with improved patient symptoms | Magnitude consistent with approximately one-grade physician global improvement. [17] | Continue effective therapy and use proactive topical maintenance at recurrent sites. [22][24] |
| EASI improves but POEM, itch, or sleep burden remains high | Objective signs and patient experience may be discordant. [18][19] | Assess xerosis, excoriation, adverse effects, and alternate contributors before changing systemic therapy. [18][19] |
| Persistent extensive inflammation and high burden after optimized topical treatment | Topical-only management is inadequate for moderate-to-severe disease. [19][23] | Select systemic therapy, phototherapy, or conventional immunosuppression according to efficacy and safety priorities. [21][23] |
| Repeated need for high-potency topical corticosteroid | Risk of local adverse effects rises with prolonged exposure; systemic effects are possible with prolonged high-potency use. [22] | Introduce steroid-sparing topical treatment and reassess need for systemic disease control. [16][22] |

## References
1. [PDF] NDA Multi-Disciplinary Review and Evaluation: CIBINQO (abrocitinib) — www.fda.gov — https://www.fda.gov/media/166519/download
2. [PDF] 219474Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/219474Orig1s000MultidisciplineR.pdf
3. Selectivity, efficacy and safety of JAKinibs: new evidence for a still ... — ard.bmj.com — https://ard.bmj.com/content/annrheumdis/early/2023/11/02/ard-2023-223850.full.pdf
4. Short-term efficacy and safety of biologics and Janus kinase ... — www.cell.com — https://www.cell.com/heliyon/pdf/S2405-8440(23)09222-8.pdf
5. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0163725821000322
6. Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2213219821001756
7. Topical and systemic corticosteroids in the modern Management of Atopic Eczema: A scoping review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1567576926003218
8. Topical and systemic corticosteroids in the modern Management of Atopic Eczema: A scoping review — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1567576926003218
9. How we treat atopic dermatitis now and how that will change over ... — academic.oup.com — https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljac116/51919009/ljac116.pdf
10. practical guide to using oral Janus kinase inhibitors for atopic ... — academic.oup.com — https://academic.oup.com/bjd/article/192/1/135/7754126
11. Add-on treatments in patients with atopic dermatitis with incomplete ... — academic.oup.com — https://academic.oup.com/ced/advance-article/doi/10.1093/ced/llag062/8651691
12. Oral Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis — academic.oup.com — https://academic.oup.com/skinhd/article/3/1/ski2.133/7755664
13. Assessing the current treatment of atopic dermatitis: Unmet needs - Journal of Allergy and Clinical Immunology — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(17)30150-1/fulltext
14. A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis - The Journal of Allergy and Clinical Immunology: In Practice — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(23)00356-2/pdf
15. A Systematic Review of the Efficacy and Safety of Probiotics in Topical Treatment of Atopic Dermatitis - Journal of Allergy and Clinical Immunology — www.jacionline.org — https://www.jacionline.org/article/S0091-6749(19)31979-7/fulltext
16. Atopic Dermatitis Part 2: Management | Pediatrics In Review — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/46/8/425/202963/Atopic-Dermatitis-Part-2-Management
17. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7862410
18. Relationship between EASI and SCORAD severity assessments for atopic dermatitis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5723207
19. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7395647
20. Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12497682
21. national institute for health and care excellence — www.nice.org.uk — https://www.nice.org.uk/guidance/gid-ta10596/documents/final-scope
22. Atopic Dermatitis: A Review of Diagnosis and Treatment - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627575
23. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/37678577
24. Strategies for using topical corticosteroids in children and adults with ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013356.pub2/full

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.